221 related articles for article (PubMed ID: 23607341)
1. Cysteine-poor region-specific EpCAM monoclonal antibody recognizing native tumor cells with high sensitivity.
Takao M; Nagai Y; Torii T
Monoclon Antib Immunodiagn Immunother; 2013 Apr; 32(2):73-80. PubMed ID: 23607341
[TBL] [Abstract][Full Text] [Related]
2. Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry.
Takao M; Takeda K
Cytometry A; 2011 Feb; 79(2):107-17. PubMed ID: 21246706
[TBL] [Abstract][Full Text] [Related]
3. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
[TBL] [Abstract][Full Text] [Related]
4. Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF.
Hall MA; Pinkston KL; Wilganowski N; Robinson H; Ghosh P; Azhdarinia A; Vazquez-Arreguin K; Kolonin AM; Harvey BR; Sevick-Muraca EM
J Nucl Med; 2012 Sep; 53(9):1427-37. PubMed ID: 22872743
[TBL] [Abstract][Full Text] [Related]
5. Detection of circulating tumor-associated antigen depends on the domains recognized by the monoclonal antibodies used: N-terminal trimmed EpCAM-levels are much higher than untrimmed forms.
Schmetzer O; Moldenhauer G; Nicolaou A; Schlag P; Riesenberg R; Pezzutto A
Immunol Lett; 2012 Apr; 143(2):184-92. PubMed ID: 22387297
[TBL] [Abstract][Full Text] [Related]
6. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
[TBL] [Abstract][Full Text] [Related]
7. Specific targeting of Ep-CAM in various carcinomas by novel monoclonal antibodies.
Sithambaram D; Palanivelu S; Subramanian K; Sahoo S; Verma RS
Hybridoma (Larchmt); 2011 Dec; 30(6):511-8. PubMed ID: 22149275
[TBL] [Abstract][Full Text] [Related]
8. Multicolor detection of rare tumor cells in blood using a novel flow cytometry-based system.
Watanabe M; Uehara Y; Yamashita N; Fujimura Y; Nishio K; Sawada T; Takeda K; Koizumi F; Koh Y
Cytometry A; 2014 Mar; 85(3):206-13. PubMed ID: 24327318
[TBL] [Abstract][Full Text] [Related]
9. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.
Fong D; Moser P; Kasal A; Seeber A; Gastl G; Martowicz A; Wurm M; Mian C; Obrist P; Mazzoleni G; Spizzo G
Histopathology; 2014 Apr; 64(5):683-92. PubMed ID: 24117877
[TBL] [Abstract][Full Text] [Related]
10. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
[TBL] [Abstract][Full Text] [Related]
11. The detection of EpCAM(+) and EpCAM(-) circulating tumor cells.
de Wit S; van Dalum G; Lenferink AT; Tibbe AG; Hiltermann TJ; Groen HJ; van Rijn CJ; Terstappen LW
Sci Rep; 2015 Jul; 5():12270. PubMed ID: 26184843
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.
Ruf P; Gires O; Jäger M; Fellinger K; Atz J; Lindhofer H
Br J Cancer; 2007 Aug; 97(3):315-21. PubMed ID: 17622246
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies.
Antolovic D; Galindo L; Carstens A; Rahbari N; Büchler MW; Weitz J; Koch M
BMC Biotechnol; 2010 Apr; 10():35. PubMed ID: 20426872
[TBL] [Abstract][Full Text] [Related]
14. Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer.
Liao MY; Kuo MY; Lu TY; Wang YP; Wu HC
Int J Oncol; 2015 Apr; 46(4):1788-800. PubMed ID: 25652097
[TBL] [Abstract][Full Text] [Related]
15. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
[TBL] [Abstract][Full Text] [Related]
16. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.
Patriarca C; Macchi RM; Marschner AK; Mellstedt H
Cancer Treat Rev; 2012 Feb; 38(1):68-75. PubMed ID: 21576002
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines.
Sterzynska K; Kempisty B; Zawierucha P; Zabel M
Folia Histochem Cytobiol; 2012; 50(4):534-41. PubMed ID: 23264216
[TBL] [Abstract][Full Text] [Related]
18. In vitro detection of circulating tumor cells compared by the CytoTrack and CellSearch methods.
Hillig T; Horn P; Nygaard AB; Haugaard AS; Nejlund S; Brandslund I; Sölétormos G
Tumour Biol; 2015 Jun; 36(6):4597-601. PubMed ID: 25608842
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
